Key facts
- This page summarizes Alan Seth Krasner's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Oct 2023, 17:01.
Alan Seth Krasner - 17 Oct 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CRNX
- Reported as of
- 17 Oct 2023
- Net transaction value
- -$125,930
- SEC form
- 4
- Accepted by SEC
- 19 Oct 2023, 17:01:13 UTC
- Prior SEC filing
- 17 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc Wilson, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alan Seth Krasner filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 19 Oct 2023.
Change
- Previous filing in this sequence was filed on 17 Mar 2023.
- Current net transaction value: -$125,930.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- $84,070
- Shares
- +7,000
- Change %
- +16%
- Price
- $12.01
- Shares after
- 50,210
- Date
- 17 Oct 2023
- Ownership
- Direct
- Footnotes
- F1
CRNX
transaction
Common Stock
Sale
- Transaction value
- $210,000
- Shares
- -7,000
- Change %
- -14%
- Price
- $30.00
- Shares after
- 43,210
- Date
- 17 Oct 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Non-qualified stock option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,000
- Change %
- -4.4%
- Price
- $0.000000
- Shares after
- 153,473
- Date
- 17 Oct 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,000
- Exercise price
- $12.01
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 2 footnotes
Footnote F1
Includes 909 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.
Footnote F2
25% of the shares subject to the option vest on June 16, 2019, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. The stock options are also subject to accelerated vesting as set forth in the employment agreement between the Issuer and the Reporting Person.